Download PDF

1. Company Snapshot

1.a. Company Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus.


It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J.Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG.to develop antisense therapies in the field of neurodegenerative diseases.


The company was formerly known as SPR Pharma Inc.and changed its name to Denali Therapeutics Inc.in March 2015.


Denali Therapeutics Inc.was incorporated in 2013 and is headquartered in South San Francisco, California.

Show Full description

1.b. Last Insights on DNLI

Denali Therapeutics' recent performance has been driven by several positive factors. The FDA approval of Avlayah, its breakthrough Hunter syndrome therapy, has been a significant catalyst. The company's plan for commercial launch and potential revenue growth from this therapy are encouraging. Institutional investors have shown confidence in the stock, with SG Americas Securities LLC increasing its holdings by 291.6% and Capricorn Fund Managers Ltd acquiring a new position. Additionally, Denali regained full rights to investigational therapy DNL593, allowing for full control and potential acceleration of development. Analysts have a consensus "Moderate Buy" rating on the stock.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?

Apr -17

Source:

Card image cap

Denali Stock Falls as Partner Takeda Ends Collaboration Deal

Apr -07

Source: zacks.com

Card image cap

Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

Apr -06

Source: benzinga.com

Card image cap

Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI

Apr -06

Source: defenseworld.net

Card image cap

SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI

Apr -05

Source: defenseworld.net

Card image cap

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts

Apr -05

Source: defenseworld.net

Card image cap

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Apr -03

Source: globenewswire.com

Card image cap

Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up

Mar -26

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Therapeutics

Expected Growth: 10.43%

Denali Therapeutics' 10.43% growth is driven by its innovative pipeline of neurodegenerative disease treatments, strong partnerships with Biogen and Sanofi, and increasing R&D investments. The company's focus on blood-brain barrier penetration technology and its potential to address unmet medical needs in Alzheimer's and Parkinson's diseases also contribute to its growth momentum.

7. Detailed Products

DNL151

A small molecule inhibitor of RIPK1, a key regulator of necroptosis and inflammation, for the treatment of ALS and other neurodegenerative diseases.

DNL201

A small molecule inhibitor of LRRK2, a key regulator of lysosomal function, for the treatment of Parkinson's disease.

DNL788

A small molecule inhibitor of ATG4, a key regulator of autophagy, for the treatment of neurodegenerative diseases.

DNL593

A small molecule inhibitor of DJ-1, a key regulator of mitochondrial function, for the treatment of Parkinson's disease.

DNL519

A small molecule inhibitor of tau, a key regulator of neurodegeneration, for the treatment of Alzheimer's disease and other tauopathies.

8. Denali Therapeutics Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Denali Therapeutics Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for neurodegenerative diseases.

Bargaining Power Of Customers

Denali Therapeutics Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for effective treatments.

Bargaining Power Of Suppliers

Denali Therapeutics Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

Denali Therapeutics Inc. has a high threat of new entrants due to the growing interest in biotechnology and the potential for new companies to enter the market.

Intensity Of Rivalry

Denali Therapeutics Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 4.82%
Debt Cost 3.95%
Equity Weight 95.18%
Equity Cost 10.89%
WACC 10.56%
Leverage 5.07%

11. Quality Control: Denali Therapeutics Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
PTC Therapeutics

A-Score: 5.8/10

Value: 7.8

Growth: 5.6

Quality: 8.4

Yield: 0.0

Momentum: 9.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Revolution Medicines

A-Score: 4.3/10

Value: 6.2

Growth: 1.8

Quality: 4.5

Yield: 0.0

Momentum: 9.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Ionis Pharmaceuticals

A-Score: 4.2/10

Value: 6.0

Growth: 1.1

Quality: 4.4

Yield: 0.0

Momentum: 10.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Celldex Therapeutics

A-Score: 3.8/10

Value: 6.7

Growth: 3.0

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Amicus Therapeutics

A-Score: 3.6/10

Value: 0.4

Growth: 7.4

Quality: 4.6

Yield: 0.0

Momentum: 5.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Denali Therapeutics

A-Score: 3.3/10

Value: 6.7

Growth: 3.7

Quality: 4.5

Yield: 0.0

Momentum: 2.5

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

20.57$

Current Price

20.57$

Potential

-0.00%

Expected Cash-Flows